GlassScriptPhysician profile
Joshua L Gibson
NPI 1427646496
$2,957.97
in general payments reported to CMS, 2019-2025
31 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $451 · 2023: $982 · 2024: $854 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $360.89 | 2024-2025 | Aquabeam System |
| Sumitomo Pharma America, INC. | $356.36 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $259.68 | 2021-2024 | Erleada, Akeega |
| Teleflex LLC | $195.98 | 2023 | Urolift |
| Convatec INC. | $194.43 | 2022-2023 | |
| Antares Pharma, INC. | $182.27 | 2021-2022 | |
| Abbvie INC. | $170.64 | 2023-2024 | |
| Srs Medical Systems, INC. | $146.43 | 2023-2024 | Urocuff, Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Merck Sharp & Dohme LLC | $131.35 | 2021-2023 | Keytruda, Lynparza |
| Acerus Pharmaceuticals Corporation | $111.18 | 2021-2022 | |
| Myovant Sciences INC. | $105.60 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $76.18 | 2022-2024 | Prolaris |
| Clarus Therapeutics INC. | $73.76 | 2021 | |
| Tolmar, INC. | $73.71 | 2023 | |
| Astellas Pharma US INC | $61.16 | 2022-2025 | Xtandi, Myrbetriq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.28 | 2024-2025 | |
| Urogen Pharma, INC. | $51.95 | 2023-2024 | Jelmyto |
| Endo Pharmaceuticals INC. | $38.17 | 2022-2023 | Aveed, Edex, Xiaflex |
| Urovant Sciences INC | $37.92 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $37.36 | 2023 | Yonsa |
| Mission Pharmacal Company | $32.54 | 2022 | |
| Azurity Pharmaceuticals, INC. | $30.86 | 2025 | Azmiro |
| Novo Nordisk INC | $21.82 | 2024 | |
| Amgen INC. | $21.76 | 2021 | |
| Medtronic, INC. | $21.75 | 2024 | Interstim |
| Endo USA, INC. | $20.26 | 2024 | Xiaflex |
| 180 Medical, INC. | $19.54 | 2022 | |
| Blue Earth Diagnostics | $19.12 | 2021 | |
| Axonics, INC. | $18.91 | 2024 | Axonics |
| Accord Healthcare, INC. | $14.69 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.